Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | NQO2 | P16083 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6677069 | 0.63 | CYP19A1 (0.50) | CYP19A1NQO2ALDH1A1HPGDKDM4E | |
| SCHEMBL6806521 | 0.61 | CNR2 (0.54) | CNR2 | |
| SCHEMBL21753940 | 0.61 | ALDH1A1 (0.43) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL17221392 | 0.60 | CD274 (0.42) | ALDH1A1KDM4EMEN1KMT2AGAA | |
| SCHEMBL16479308 | 0.59 | ALDH1A1 (0.43) | CYP19A1NQO2ALDH1A1HPGDKDM4E | |
| SCHEMBL13061402 | 0.59 | CNR2 (0.59) | ALDH1A1KDM4EMAPTHTTPOLB | |
| SCHEMBL28100171 | 0.58 | ALDH1A1 (0.45) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL16479303 | 0.58 | ALDH1A1 (0.45) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL19612341 | 0.58 | SMN1; SMN2 (0.47) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28530472 | 0.58 | AOC3 (0.39) | KDM4EMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6806276-B2 | SIDE EFFECT REDUCTION ON CENTRAL NERVOUS SYSTEM; IMMUNOSUPPRESSANTS; ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | JAPAN TOBACCO INC. (JP) | 2004-10-19 | — | — | US | disclosed |
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | JAPAN TOBACCO, INC (JP) | 2003-10-09 | — | — | US | disclosed |
| US-6509352-B1 | Selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or | JAPAN TOBACCO INC. (JP) | 2003-01-21 | — | — | US | disclosed |
| EP-1142877-A1 | 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | CNR2, CNR1, OPRL1 | CYP19A1 1734/4885NQO2 2309/4885ALDH1A1 2343/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CYP19A1 3011/4885NQO2 3800/4885ALDH1A1 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.